NASDAQ:FBRX Forte Biosciences (FBRX) Stock Price, News & Analysis $11.32 +0.97 (+9.37%) Closing price 06/6/2025 04:00 PM EasternExtended Trading$11.27 -0.05 (-0.44%) As of 06/6/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Forte Biosciences Stock (NASDAQ:FBRX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Forte Biosciences alerts:Sign Up Key Stats Today's Range$10.35▼$11.3250-Day Range$5.25▼$11.5352-Week Range$4.11▼$28.68Volume18,846 shsAverage Volume158,442 shsMarket Capitalization$74.52 millionP/E RatioN/ADividend YieldN/APrice Target$61.00Consensus RatingBuy Company OverviewForte Biosciences, Inc. operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc. is headquartered in Dallas, Texas.Read More… Forte Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks59th Percentile Overall ScoreFBRX MarketRank™: Forte Biosciences scored higher than 59% of companies evaluated by MarketBeat, and ranked 428th out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingForte Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageForte Biosciences has only been the subject of 1 research reports in the past 90 days.Read more about Forte Biosciences' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Forte Biosciences are expected to grow in the coming year, from ($12.12) to ($3.68) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Forte Biosciences is -0.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Forte Biosciences is -0.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioForte Biosciences has a P/B Ratio of 0.47. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Forte Biosciences' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.44% of the float of Forte Biosciences has been sold short.Short Interest Ratio / Days to CoverForte Biosciences has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Forte Biosciences has recently increased by 18.54%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldForte Biosciences does not currently pay a dividend.Dividend GrowthForte Biosciences does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted2.44% of the float of Forte Biosciences has been sold short.Short Interest Ratio / Days to CoverForte Biosciences has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Forte Biosciences has recently increased by 18.54%, indicating that investor sentiment is decreasing significantly. News and Social Media2.5 / 5News Sentiment0.46 News SentimentForte Biosciences has a news sentiment score of 0.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.71 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Forte Biosciences this week, compared to 0 articles on an average week.Search Interest3 people have searched for FBRX on MarketBeat in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Forte Biosciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.90% of the stock of Forte Biosciences is held by insiders.Percentage Held by Institutions77.63% of the stock of Forte Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Forte Biosciences' insider trading history. Receive FBRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Forte Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address FBRX Stock News HeadlinesForte Biosciences Stock Price, Quotes and Forecasts | NASDAQ:FBRX | BenzingaJune 1, 2025 | benzinga.comForte Biosciences Target of Unusually High Options Trading (NASDAQ:FBRX)May 30, 2025 | americanbankingnews.comThe Social Security Changes No One’s Talking AboutWhile most Americans worry about their next Social Security check... something far bigger is happening behind the scenes. An AI plan — authorized by Executive Order — is about to rewrite how the SSA operates.June 7, 2025 | Altimetry (Ad)TD Cowen Remains a Buy on Forte Biosciences (FBRX)May 18, 2025 | theglobeandmail.comForte Biosciences price target lowered to $61 from $64 at ChardanApril 2, 2025 | markets.businessinsider.comIs Forte Biosciences (NASDAQ:FBRX) In A Good Position To Deliver On Growth Plans?April 1, 2025 | finance.yahoo.comForte Biosciences (FBRX) Gets a Buy from TD CowenApril 1, 2025 | markets.businessinsider.comForte Biosciences, Inc. Announces Results and Provides Clinical UpdateMarch 31, 2025 | finance.yahoo.comSee More Headlines FBRX Stock Analysis - Frequently Asked Questions How have FBRX shares performed this year? Forte Biosciences' stock was trading at $22.71 at the beginning of the year. Since then, FBRX stock has decreased by 50.2% and is now trading at $11.32. View the best growth stocks for 2025 here. How were Forte Biosciences' earnings last quarter? Forte Biosciences, Inc. (NASDAQ:FBRX) posted its quarterly earnings data on Thursday, May, 15th. The company reported ($1.37) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.89) by $0.48. Who are Forte Biosciences' major shareholders? Forte Biosciences' top institutional shareholders include Fred Alger Management LLC (13.83%), AlphaQuest LLC (0.06%) and Garde Capital Inc. (0.06%). Insiders that own company stock include Paul A Wagner and Antony A Riley. View institutional ownership trends. How do I buy shares of Forte Biosciences? Shares of FBRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Forte Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Forte Biosciences investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), PayPal (PYPL), QUALCOMM (QCOM), Avino Silver & Gold Mines (ASM), Avino Silver & Gold Mines (ASM) and Meta Platforms (META). Company Calendar Last Earnings5/15/2025Today6/07/2025Next Earnings (Estimated)8/13/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:FBRX CIK1419041 Webwww.fortebiorx.com Phone(310) 618-6994FaxN/AEmployees5Year FoundedN/APrice Target and Rating Average Stock Price Target$61.00 High Stock Price Target$61.00 Low Stock Price Target$61.00 Potential Upside/Downside+438.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($16.29) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$31.48 million Net MarginsN/A Pretax MarginN/A Return on Equity-151.43% Return on Assets-118.92% Debt Debt-to-Equity RatioN/A Current Ratio2.06 Quick Ratio2.06 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$24.30 per share Price / Book0.47Miscellaneous Outstanding Shares6,583,000Free Float6,195,000Market Cap$74.52 million OptionableOptionable Beta2.85 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (NASDAQ:FBRX) was last updated on 6/7/2025 by MarketBeat.com Staff From Our PartnersAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Forte Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Forte Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.